News

Multiple sclerosis (MS) patients who smoke have a significantly worse quality of life than non-smoking MS patients, concludes a new study. Researchers presented the study, “Smokers with MS have greater decrements in quality of life and disability than non-smokers,” at the Americas Committee for Treatment and Research in…

In a U.S. nationwide case study, a team of researchers found evidence for a potential link between viral infections during childhood, vitamin D deficiency, and the risk of developing multiple sclerosis (MS). The study, “Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited,” was recently…

A 60-year follow-up study of nearly 1,400 Norwegian patients with multiple sclerosis (MS) analyzed their survival and risk of dying starting with the onset of the disease through its progression. The study, “A 60- year follow-up on survival and cause of death in multiple sclerosis in Western Norway,” was recently…

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching no evidence of disease activity (NEDA), according to a new analysis. The study, “NEDA analysis by epoch in patients with relapsing multiple…

Ten years after completing treatment with Novantrone (mitoxantrone), a chemotherapy drug, multiple sclerosis (MS) patients showed evidence of markedly lower annualized relapse rates, but the therapy’s effects began to wane after five years, a study presented at ACTRIMS 2017 Forum reported. The study also assessed how Novantrone affects disease progression in primary and secondary progressive…

The absence of epigenetic factors in myelin-producing oligodendrocyte cells make sure that myelin production is switched off in the adult brain. Targeting these factors may be a way of triggering myelin regeneration in multiple sclerosis (MS), and a step toward personalized medicine for this disease, Dr. Patrizia Casaccia said in a talk…

Multiple sclerosis (MS) is thought to be caused by genetic factors, but environmental cues are increasingly recognized to have an impact on disease onset and development. One environmental factor suggested to play a role in MS is infectious agents, such as viruses. Now, different teams of scientists have explored the…

Sex hormones, and genes in the two sex chromosomes, impact the risk of multiple sclerosis (MS) in men and women differently, and lead to differences in the course of the disease between the sexes, according to two studies. Two speakers at the ACTRIMS 2017 Forum highlighted the role of sex…

New evidence strengthens the link between a diet high in salt and multiple sclerosis (MS) development, researchers show. The study, “Sodium Chloride Intake and MS,” was presented on Feb. 24 at the ACTRIMS) 2017 Forum being held in Orlando, Florida, by Dr. David Hafler with the Yale School of Medicine. The…

A detailed analysis of relapsing and primary progressive multiple sclerosis (MS) patients in the three Phase 3 trials of Ocrevus (ocrelizumab) showed that the treatment did not significantly increase their risk of infections — serious or otherwise. Certain infections, including common colds and influenza, were numerically more common among Ocrevus-treated patients,…

Short-chain dietary fatty acids, such as propionate, drive the production of regulatory immune T-cells in patients with multiple sclerosis (MS), while long-chain acids promote T-cells that are involved in inflammatory processes. Since the beneficial fatty acids are safe and can be obtained as over-the-counter dietary supplements, researchers suggest they could…

Spending more time in the sunshine could make people with multiple sclerosis (MS) feel more energetic, though dietary vitamin D intake’s effect is mixed, depending on what type of MS a particular patient has. That’s the conclusion of a study — “Dietary intakes of vitamin D, sunshine exposure, EDSS and fatigue…

Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the absence of further treatment. Both studies were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum, held…

Genentech’s Ocrevus (ocrelizumab) increased the proportion of patients with no evidence of progression (NEP) in the recently concluded ORATORIO Phase 3 clinical trial in patients with primary progressive multiple sclerosis (PPMS). The evaluation of NEP — a combined measure of three disability assessments — was a secondary exploratory endpoint of…

First-degree relatives of multiple sclerosis (MS) patients may develop asymptomatic disease, suggesting the need to further evaluate family members to develop timely prevention strategies. The study, “Investigating early evidence of multiple sclerosis in a prospective study of high risk family members,” was presented at the Americas Committee for Treatment and…

Disease processes in multiple sclerosis (MS) likely contribute to the increased sensitivity to airway infections seen in MS patients, a series of experiments in mice demonstrated. The study, presented at the ACTRIMS 2017 Forum, showed that suppressive immune cells travel to the lungs and prevent an essential inflammatory reaction to viral…

The Brazilian government has authorized HempMeds Brasil, a unit of California-based Medical Marijuana, to import the parent company’s hemp cannabidiol (CBD) oil flagship product — known as Real Scientific Hemp Oil (RSHO) — for the management of multiple sclerosis (MS) symptoms. This is the first time Brazil’s National Health Surveillance Agency…

Treatment with Apitope’s lead agent, ATX-MS-1467, decreased brain lesions in patients with relapsing multiple sclerosis (MS) in a now-completed Phase 2a clinical trial. ATX-MS-1467 is a potential disease-modifying agent with an immune-tolerating action. It consists of four short peptides derived from the myelin basic protein, and is designed to reduce…

Treatment with a compound called BIIB074 shows promise in reducing pain caused by trigeminal neuralgia — a  condition that occasionally affects multiple sclerosis (MS) patients — with few side effects, a new clinical trial finds. The Swiss study, “Safety and efficacy of a Nav1.7 selective sodium channel blocker in Titrigeminal neuralgia:…

Results from a Phase 2 proof-of-concept study of ADS-5102 (amantadine HCl), showing that multiple sclerosis patients given the extended-release oral treatment improved their walking speed, will be presented at ACTRIMS 2017 this week. Findings in the poster, “A Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,”…

Stem cell transplants are most effective if done in young multiple sclerosis (MS) patients in early disease stages, who have not gone through several rounds of other treatments, according to a large study that followed transplant patients for more than five years. Study results also found that people with relapsing MS are much…

A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients with relapsing multiple sclerosis (RMS) shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058) tested ozanimod, an oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…

The second annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), a forum for clinicians, researchers and other MS specialists to network and discuss the  latest advances in MS research and treatment is set for Feb. 23–25. This year’s meeting takes place at the Omni ChampionsGate resort hotel in Orlando, Florida. Multiple Sclerosis News…

Dolly Stokes, a fitness trainer and multiple sclerosis (MS) patient, and her husband, Jeff Stokes, have launched the website for their fitness and wellness company, BFitLifestyles, providing information on how to live an active and healthy life. The Stokes, owners of three fitness-related companies in Fairhope, Alabama – DollyBFitness, BFitLifestyles, and Stokes…

The French economic promotion agency Bpifrance has awarded Boston-based PathMaker Neurosystems a grant to finance the development of its MyoRegulator, a noninvasive neurotherapy technology to treat conditions linked to neural pathway disruption, including neuromotor spasticity in patients with multiple sclerosis (MS). Through the Programme d’Investissements d’Avenir (PIA-1), an investment program offered by Bpifrance, the  grant — whose…

Canadian researchers are testing mice to see if cannabinoid oil products — a common medical marijuana treatment — could help alleviate the neuropathic pain that often afflicts patients with multiple sclerosis (MS). The preclinical study, “Identifying the molecular mechanisms involved in supressing multiple sclerosis induced neuropathic pain following cannabinoid treatment in…

The world’s first registry for patients with multiple sclerosis (MS) and other autoimmune diseases (ADs) has gone online, to honor National Autoimmune Disease Awareness Month in March. The Autoimmune Research Network (ARNet) is a creation of the Michigan-based American Autoimmune Related Diseases Association (AARDA), which is collaborating with the National Coalition of…

The U.S. Food and Drug Administration (FDA) has authorized the use of Bioness’ L300 Go System electrical-stimulation rehabilitation device for multiple sclerosis (MS) patients and others with walking impairment. It is the first electrical stimulation device to offer 3D motion detection of gait and muscle activation, the company says. The L300…

Gilenya (fingolimod) a multiple sclerosis (MS) drug developed to target the immune system and control inflammation, can also reduce the negative action of astrocytes, further controlling inflammation, says a new study. The article, “Sphingosine 1-Phosphate Receptor Modulation Suppresses Pathogenic Astrocyte Activation and Chronic Progressive CNS Inflammation,” appeared in the…

Researchers have tested a new compound called ST266 in a mouse model of multiple sclerosis (MS) and found that its anti-inflammatory properties prevent the loss of cells related to optic neuritis — a condition that leads to vision loss. The study, “Intranasal Delivery of a Novel Amnion Cell Secretome Prevents…